Roche’s Phase III TIGIT Failure In Metastatic SCLC Disappoints But Is Small Loss
Executive Summary
Tiragolumab missed several endpoints in a Phase III metastatic SCLC study, and hopes now rest on its success in NSCLC which presents the bigger market opportunity for the lead candidate in this closely watched new drug class.
You may also be interested in...
Blow To Roche Growth Prospects As TIGIT Lung Cancer Trial Fails
Failure of the tiragolumab plus Tecentriq combination in first line NSCLC patients is a blow to Roche’s immunotherapy aspirations, and its long-term growth strategy.
As Tecentriq Growth Slows, Roche’s Imminent TIGIT Readout Is Crucial
One of the year’s most important trial readouts is for Roche’s potential first-in-class TIGIT inhibitor, tiragolumab, and could help reverse a slowdown in blockbuster immunotherapy Tecentriq's growth.
Readouts For TIGIT And Alzheimer’s Drugs Will Define Roche’s Year
Roche has a lot riding on it trials to extend use of Tecentriq to challenge Keytruda in frontline NSCLC – but the wait for its Alzheimer’s readout for gantenerumab will be truly nerve-wracking.